rs6885099 — PDE8B PDE8B TSH variant

Intronic TSH quantitative trait locus in phosphodiesterase 8B — the G allele raises the thyroid set-point, increasing hypothyroidism risk and potentially affecting levothyroxine dose requirements

See your personal result for PDE8B

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PDE8B — The Phosphodiesterase That Sets Your Thyroid's Thermostat

Your thyroid gland operates like a thermostat: the pituitary hormone TSH (thyroid-stimulating hormone)11 TSH (thyroid-stimulating hormone)
Thyrotropin — secreted by the anterior pituitary, it binds TSH receptors on thyroid follicular cells and drives synthesis and release of T3 and T4. The pituitary adjusts TSH output based on feedback from circulating thyroid hormone levels signals the thyroid to produce more or less hormone. But the gain on that thermostat varies between individuals — and PDE8B is a key control knob.

PDE8B encodes phosphodiesterase 8B22 phosphodiesterase 8B
A cyclic nucleotide phosphodiesterase highly expressed in thyroid tissue that specifically degrades cAMP (cyclic adenosine monophosphate). cAMP is the second messenger through which TSH stimulates thyroid hormone production an enzyme that degrades cAMP inside thyroid follicular cells. When TSH binds its receptor, it triggers a cAMP surge that drives thyroid hormone synthesis. PDE8B acts as a brake on that surge: higher PDE8B activity → faster cAMP degradation → weaker thyroid response to TSH → the pituitary compensates by raising circulating TSH levels. rs6885099 sits in intron 1 of PDE8B and influences how much of this enzyme the thyroid makes.

The Mechanism

rs6885099 is an intronic quantitative trait locus (QTL)33 quantitative trait locus (QTL)
A genetic variant that influences the quantity of a measurable trait — here, serum TSH levels — without altering protein structure. These variants typically act through regulatory elements (enhancers, splicing signals) embedded within introns or non-coding regions affecting PDE8B gene expression in thyroid tissue. The G allele is associated with higher PDE8B activity or expression, which accelerates cAMP degradation and raises the thyroid's effective TSH threshold. The result is a genetically-programmed upward shift in the individual's TSH set-point — circulating TSH is chronically higher relative to tissue thyroid hormone levels.

Critically, this is not the same as thyroid disease: individuals with GG or AG genotypes have a higher TSH set-point but are often euthyroid (normal circulating T3/T4). However, they may tip into subclinical hypothyroidism44 subclinical hypothyroidism
TSH above the upper reference range with normal free T4 — the most common form of thyroid dysfunction, affecting 4-10% of the general population and up to 20% of women over 60 at lower absolute levels of thyroid dysfunction, and when they do require levothyroxine replacement, their genetically higher set-point may require a higher dose to suppress TSH adequately.

The Evidence

The largest study to date is the Rand et al. 202555 Rand et al. 2025
Rand SA et al. Genome-wide association study and polygenic risk prediction of hypothyroidism. Nat Genet, 2025 meta-analysis in 113,393 hypothyroidism cases and 1,065,268 controls — identifying 350 associated loci. rs6885099-G showed one of the strongest signals (beta = 0.10, p = 1×10⁻⁹³), confirming PDE8B as a major determinant of hypothyroidism susceptibility.

The TSH-lowering effect of the A allele was established by Porcu et al. 201366 Porcu et al. 2013
Porcu E et al. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genet, 2013 in up to 26,420 euthyroid subjects: the rs6885099-A allele reduced log-TSH by 0.141 units (p = 2×10⁻²⁶), with a stronger effect in males (beta −0.168, p = 3×10⁻³⁸) than females (beta −0.12, p = 6×10⁻²⁴), suggesting partial sex-hormone modulation of PDE8B activity.

Soto-Pedre et al. 201777 Soto-Pedre et al. 2017
Soto-Pedre E et al. Replication confirms the association of loci in FOXE1, PDE8B, CAPZB and PDE10A with thyroid traits: a GoDARTS study. Pharmacogenet Genomics, 2017 confirmed the locus in 1,703 hypothyroidism cases and 9,457 controls; PDE8B variants collectively explained 6.8% of TSH variance.

Wade et al. 202588 Wade et al. 2025
Wade AN et al. Strength of Genetic Associations with Thyrotropin Values Differs Between Populations with Similarity to African and European Reference Populations. Thyroid, 2025 found that PDE8B was not significantly associated with TSH in African-ancestry populations despite strong effects in Europeans — an important caveat for interpreting the result in non-European individuals.

Practical Actions

For GG and AG individuals, the main clinical implications are: (1) awareness of a higher baseline TSH that may require lower thresholds for hypothyroidism diagnosis, (2) for those already on levothyroxine, the TSH target may need adjustment relative to standard ranges, and (3) monitoring iodine intake — since thyroid hormone synthesis requires iodine, marginal iodine status combined with a high-PDE8B set-point amplifies hypothyroidism risk.

Selenium supports deiodinase enzymes99 deiodinase enzymes
Selenoproteins that convert the storage form T4 to the active T3; selenium deficiency impairs this conversion and may worsen functional hypothyroidism even when TSH is only mildly elevated that convert inactive T4 to active T3. GG carriers benefit specifically from ensuring selenium adequacy.

Interactions

rs4704397 (PDE8B intron 1) is in strong linkage disequilibrium with rs6885099 and captures overlapping variance. Both variants have been studied for TSH effects; their combined information adds little beyond either alone.

rs2046045 (PDE8B intron 1) is a third correlated variant in the same LD block, consistently identified in GWAS of TSH and hypothyroidism.

rs11206244 (TPO — thyroid peroxidase) affects thyroid hormone synthesis directly rather than cAMP signaling, acting through a different pathway. Individuals combining a high PDE8B set-point (this SNP) with impaired TPO activity may have compounded hypothyroidism risk.

Drug Interactions

levothyroxine dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

AA Low TSH Set-Point Normal

Reference alleles — lower TSH set-point, reduced hypothyroidism risk

In the Porcu et al. 2013 meta-analysis of 26,420 euthyroid subjects, the A allele was associated with a −0.141 log-unit reduction in TSH per allele (p = 2×10⁻²⁶). In the Rand et al. 2025 Nature Genetics hypothyroidism GWAS, the A allele was protective against hypothyroidism (beta = −0.10, p = 1×10⁻⁹³ for the G allele). AA homozygotes have the lowest genetically-programmed TSH set-point of the three genotypes.

This does not guarantee normal thyroid function — TSH is influenced by many genes, nutritional status, autoimmunity, and age. But at this specific locus, your genetic contribution pushes toward lower TSH and reduced risk of hypothyroidism.

AG Intermediate TSH Set-Point Intermediate

One risk allele — mildly elevated TSH set-point

Under the additive inheritance model confirmed by multiple GWAS, each G allele contributes independently to higher TSH levels. AG carriers sit midway between the low set-point of AA and the high set-point of GG. In European populations, the G allele frequency is approximately 0.40, making AG the modal genotype.

The elevated set-point is typically within normal TSH reference ranges (0.4–4.0 mU/L) but sits higher within that range. This increases the probability of crossing into subclinical hypothyroidism (TSH > 4.0–4.5 mU/L) during periods of thyroid stress — iodine deficiency, autoimmune challenge, pregnancy, or aging. The Rand et al. 2025 GWAS confirmed that the PDE8B locus effect on hypothyroidism risk is additive.

For individuals already on levothyroxine, an AG genotype at this locus may mean that the TSH target needed to feel well is in the lower-normal range rather than mid-range.

GG High TSH Set-Point High Risk

Two risk alleles — elevated TSH set-point, increased hypothyroidism susceptibility

The GG genotype means your thyroid cells degrade cAMP more efficiently after TSH stimulation, blunting the hormone production response. To compensate, your pituitary secretes more TSH — chronically. This higher baseline TSH does not always cause symptoms or disease, but it narrows the margin before TSH crosses into the subclinical or overt hypothyroidism range.

In the Porcu et al. 2013 GWAS, the per-allele effect of G on log-TSH was +0.141 units (additive), meaning GG homozygotes have approximately +0.28 log-units higher TSH than AA individuals — roughly a 32% higher absolute TSH at the same level of thyroid function.

For individuals with GG genotype already on levothyroxine replacement: the genetically higher TSH set-point means the conventional TSH target (0.5–2.5 mU/L) may underestimate how much T4 your specific system requires. Multiple studies have documented that some patients on levothyroxine feel better — and show better metabolic markers — when TSH is maintained in the lower third of the reference range. Your GG genotype is one reason your treating physician might aim for a TSH target of 0.5–1.5 mU/L rather than 2.0–4.0 mU/L.

Note: the PDE8B effect on TSH is attenuated in African-ancestry individuals (Wade et al. 2025), so the magnitude of this risk prediction is most applicable to those of European descent.